Clinical Trials Logo
  1. Home
  2. HCC
  3. NCT05450874
  4. Details
NCT05450874 Clinical Trial

A Novel MSE Score to Predict rHCC Patients

HCC Clinical Trial

Official title:
A Novel MSE Score to Predict the Postoperative Prognosis of Patients With Ruptured Hepatocellular Carcinoma

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05450874
Other study ID # 2019CFB433
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2010
Est. completion date June 1, 2022

Study information
Verified date June 2022
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Develop and validate a novel scoring system based on pathological factors to predict the postoperative survival of patients with rHCC.Patients with rHCC who underwent hepatectomy were recruited from two hospitals.Exploring whether this scoring system is related to prognosis

Recruitment information / eligibility
Status Completed
Enrollment 300
Est. completion date June 1, 2022
Est. primary completion date March 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - a diagnosis of ruptured tumor confirmed by enhanced computed tomography (CT) and/or abdominal magnetic resonance imaging (MRI), - a diagnosis of HCC made by two experienced pathologists Exclusion Criteria: - extrahepatic HCC metastasis - death within 1 month after surgery

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• hepatectomy

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Tongji Hospital

Outcome
Type Measure Description Time frame Safety issue
Primary overall survival Time from the first postoperative day to survival at the last follow-up 2010-2022
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05458115 - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Enrolling by invitation NCT02256514 - Open Label Trial of Immunotherapy for Advanced Liver Cancer Phase 2
Not yet recruiting NCT06434480 - SBRT in HCC With Oligoprogression on Atezo-Bev N/A
Completed NCT04542837 - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT05025592 - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed NCT04172506 - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05840133 - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Not yet recruiting NCT06024252 - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Terminated NCT02785874 - Statin With Palliative Therapy for HCC N/A
Not yet recruiting NCT02715492 - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Phase 3
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Not yet recruiting NCT06069947 - SALT for Liver Cirrhosis With HCC N/A
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Suspended NCT02935478 - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation N/A
Recruiting NCT05592171 - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05544253 - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC Phase 2/Phase 3
Recruiting NCT06184152 - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed NCT02675920 - A Study of HCC High Risk Group Using Two Surveillance Tools